Business Description
Rohto Pharmaceutical Co Ltd
ISIN : JP3982400008
Description
Rohto Pharmaceutical Co Ltd is a Japan-based manufacturer and marketer of pharmaceutical products, cosmetics, and functional foods. It undertakes manufacture and sales activities mainly in the health and beauty care categories. The company comprises the four geographical reportable segments of Japan, America, Europe, and Asia. In each segment, it manufactures and sales eye care products including eye drops and eyewash preparations, skincare products including dermal medicines, lip balm, sunscreens, and functional cosmetics, among others, internal medicines and food products including gastrointestinal medicines, traditional Chinese herbal medicines and supplements, and other products and services, such as in-vitro test kits.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.45 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.18 | |||||
| Debt-to-EBITDA | 1.06 | |||||
| Interest Coverage | 171.52 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 4.66 | |||||
| Beneish M-Score | -2.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 14.4 | |||||
| 3-Year EBITDA Growth Rate | 19 | |||||
| 3-Year EPS without NRI Growth Rate | 20.4 | |||||
| 3-Year FCF Growth Rate | 37.7 | |||||
| 3-Year Book Growth Rate | 16.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 8.26 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12.1 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 100 | |||||
| 12-1 Month Momentum % | 0.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.84 | |||||
| Quick Ratio | 1.29 | |||||
| Cash Ratio | 0.58 | |||||
| Days Inventory | 156.05 | |||||
| Days Sales Outstanding | 60.9 | |||||
| Days Payable | 56.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.26 | |||||
| 3-Year Dividend Growth Rate | 26 | |||||
| Shareholder Yield % | -0.37 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 57.38 | |||||
| Operating Margin % | 13.07 | |||||
| Net Margin % | 9.67 | |||||
| FCF Margin % | 8.31 | |||||
| ROE % | 11.22 | |||||
| ROA % | 7.62 | |||||
| ROIC % | 10.55 | |||||
| ROC (Joel Greenblatt) % | 30.59 | |||||
| ROCE % | 14.16 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 23.37 | |||||
| Forward PE Ratio | 15.34 | |||||
| PE Ratio without NRI | 22.75 | |||||
| Shiller PE Ratio | 35.73 | |||||
| PEG Ratio | 1.4 | |||||
| PS Ratio | 2.26 | |||||
| PB Ratio | 2.51 | |||||
| Price-to-Tangible-Book | 3.26 | |||||
| Price-to-Free-Cash-Flow | 25.15 | |||||
| Price-to-Operating-Cash-Flow | 18.6 | |||||
| EV-to-EBIT | 17.6 | |||||
| EV-to-EBITDA | 15.75 | |||||
| EV-to-Revenue | 2.36 | |||||
| EV-to-FCF | 24.29 | |||||
| Price-to-Projected-FCF | 1.55 | |||||
| Price-to-DCF (Earnings Based) | 0.81 | |||||
| Price-to-DCF (FCF Based) | 1.21 | |||||
| Price-to-Median-PS-Value | 1.14 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.09 | |||||
| Price-to-Graham-Number | 1.81 | |||||
| Price-to-Net-Current-Asset-Value | 12.79 | |||||
| Earnings Yield (Greenblatt) % | 5.68 | |||||
| FCF Yield % | 3.77 | |||||
| Forward Rate of Return (Yacktman) % | 18.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rohto Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 34,124.731 | ||
| EPS (TTM) (MXN) | 14.26 | ||
| Beta | 0.05 | ||
| Volatility % | 0.81 | ||
| 14-Day RSI | 100 | ||
| 14-Day ATR (MXN) | 0.000007 | ||
| 20-Day SMA (MXN) | 320.18 | ||
| 12-1 Month Momentum % | 0.13 | ||
| 52-Week Range (MXN) | 319.775 - 320.18 | ||
| Shares Outstanding (Mil) | 228.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rohto Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rohto Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rohto Pharmaceutical Co Ltd Frequently Asked Questions
What is Rohto Pharmaceutical Co Ltd(MEX:4527)'s stock price today?
The current price of MEX:4527 is MXN320.18. The 52 week high of MEX:4527 is MXN320.18 and 52 week low is MXN319.77.
When is next earnings date of Rohto Pharmaceutical Co Ltd(MEX:4527)?
The next earnings date of Rohto Pharmaceutical Co Ltd(MEX:4527) is .
Does Rohto Pharmaceutical Co Ltd(MEX:4527) pay dividends? If so, how much?
Rohto Pharmaceutical Co Ltd(MEX:4527) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers